SCHEMBL2934339

SCHEMBL2934339

CSc1nccc(-c2cc(C#N)c(O)nc2-c2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.41
KDM4E B2RXH2 2/20 0.40
CTSS P25774 3/20 0.40
KMO O15229 1/20 0.40
LMNA P02545 2/20 0.39
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSK P43235 3/20 0.37
XDH P47989 1/20 0.37
KDM5A P29375 1/20 0.37
SCN9A Q15858 2/20 0.37
CSNK1D P48730 1/20 0.37
JAK3 P52333 1/20 0.37
KCNH2 Q12809 1/20 0.36
TOP2A P11388 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929605 0.89 MAPK14 (0.41) MAPK14KDM4ECTSSKMOLMNA
SCHEMBL2929905 0.86 L3MBTL1 (0.47) MAPK14KDM4ELMNAMAPK13MAPK12
SCHEMBL2926388 0.83 MAPK14 (0.53) MAPK14KDM4ELMNAMAPK13MAPK12
SCHEMBL6999911 0.81 MAPK14 (0.47) MAPK14KMOLMNAMAPK13MAPK12
SCHEMBL7670220 0.79 MAPK14 (0.44) MAPK14KDM4ECTSSKMOLMNA
SCHEMBL7668957 0.79 KDM4E (0.41) KDM4ECTSSKMOLMNAMAPK1
SCHEMBL7222330 0.78 MAPK14 (0.52) MAPK14KMOLMNAMAPK13MAPK12
SCHEMBL11467792 0.77 LMNA (0.58) MAPK14KDM4ECTSSKMOLMNA
SCHEMBL7676136 0.77 MAPK14 (0.50) MAPK14KMOLMNAMAPK13MAPK12
SCHEMBL1384875 0.77 MAPK14 (0.45) MAPK14KMOLMNAMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP disclosed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885KDM4E 3384/4885CTSS 3265/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885KDM4E 3953/4885CTSS 4292/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885KDM4E 3953/4885CTSS 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.